Reardon Tighe 4
4 · Janux Therapeutics, Inc. · Filed Jan 5, 2022
Insider Transaction Report
Form 4
Reardon Tighe
Acting Chief Financial Officer10% Owner
Transactions
- Award
Stock Option (right to buy)
2022-01-03+116,750→ 116,750 totalExercise: $20.24Exp: 2032-01-02→ Common Stock (116,750 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.